Journal
CELL TRANSPLANTATION
Volume 17, Issue 7, Pages 753-762Publisher
SAGE PUBLICATIONS INC
DOI: 10.3727/096368908786516819
Keywords
Parkinson's disease; Huntington's disease; Striatum; Stem cell transplants
Funding
- NIH Stein Cell Training Program [T32AG027566]
- Department of Defense [DAMD17-03-1-0122]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS057778] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [T32AG027566] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The use of human neural progenitor cells (hNPC) has been proposed to provide neuronal replacement or astrocytes delivering growth factors for brain disorders Such as Parkinson's and Huntington's disease. Success in such studies likely requires migration from the site of transplantation and integration into host tissue in the face of ongoing damage. In the current Study, hNPC modified to release glial cell line-derived neurotrophic factor (hNPC(GDNF)) were transplanted into either intact or lesioned animals. GDNF release itself had no effect oil the survival. migration, or differentiation of the cells. The most robust migration and survival was found using a direct lesion of striatum (Huntington's model) with indirect lesions of the dopamine system (Parkinson's model) or intact animals showing successively less migration and Survival. No lesion affected differentiation patterns. We conclude that the type of brain injury dictates migration and integration of hNPC. which has important consequence when considering transplantation of these cells as a therapy for neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available